FRANKLIN
LAKES, N.J., March 21,
2024 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration
(FDA) Safety Communication, which provided important updates on
FDA's ongoing evaluation of certain plastic syringes:
Eric Borin, president of BD
Medication Delivery Solutions said, "BD has the capacity to support
additional syringe demand and is further increasing U.S. production
to help ensure continuity of patient care. Since the initial FDA
safety communication in November, BD has increased domestic
manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer
needs.
"Ensuring the safety and quality of our products is the top
priority at BD. The latest FDA safety communication does not
include any BD syringes. Over our more than 125-year history, we
have served the health care system's need for essential high
quality medical products, including manufacturing 2 billion
additional syringes and needles to support the global pandemic
response to COVID-19. BD remains committed to supporting the health
care system and patients, and our clinical staff are prepared to
support customers with any questions they may have regarding our
products."
For more information on BD's commitment to quality, safety and
our customers, please visit:
https://www.bd.com/en-us/about-bd/quality-at-bd.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines
of health care by developing innovative technology, services
and solutions that help advance both clinical therapy for patients
and clinical process for health care providers. BD and
its more than 70,000 employees have a passion and commitment to
help enhance the safety and efficiency of clinicians' care delivery
process, enable laboratory scientists to accurately detect disease
and advance researchers' capabilities to develop the next
generation of diagnostics and therapeutics. BD has a
presence in virtually every country and partners with organizations
around the world to address some of the most challenging global
health issues. By working in close collaboration with
customers, BD can help enhance outcomes, lower costs,
increase efficiencies, improve safety and expand access to health
care. For more information on BD, please
visit bd.com or connect with us on LinkedIn
at www.linkedin.com/company/bd1/, X (formerly
Twitter) @BDandCo or
Instagram @becton_dickinson.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Troy
Kirkpatrick
|
Adam Reiffe
|
VP, Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.6927
|
troy.kirkpatrick@bd.com
|
adam.reiffe@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-increases-domestic-production-to-support-us-health-care-need-for-syringes-302095818.html
SOURCE BD (Becton, Dickinson and Company)